drugset / Trial / NCT05431608
A Study of MCARH109 and MCARH125 in People With Multiple Myeloma
Non-randomizedFactorialOpen-labelTreatment
Summary
A sample of participants' T cells will be sent to a laboratory, where the cells will be made into the study therapy, MCARH109 and MCARH125. Participants will receive either MCARH125 alone or MCARH125 with MCARH109.
Timeline
- Start
- 2022-06-20
- Primary completion
- 2027-06-20
- Completion
- 2027-06-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MCARH109 | Cell therapy | 0 cells | — |
| Subject | MCARH109 | Cell therapy | 50 cells | — |
| Subject | MCARH109 | Cell therapy | 150 cells | — |
| Subject | MCARH125 | Cell therapy | 50 cells | — |
| Subject | MCARH125 | Cell therapy | 150 cells | — |